An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib

  • Cancer
  • Lung Cancer
  • Non-Small Cell Lung Cancer (NSCLC)
  • Non Small Cell Lung Carcinoma
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:

Active, not recruiting

This study runs in
Cities
  • Abu Dhabi
  • Adana
  • Ankara
  • Antalya
  • Auderghem
  • Barnaul
  • Bedford Park
  • Beograd
  • bogota--d-c-
  • Bogotá
  • Brescia
  • Brno
  • București
  • Burgas
  • Cagliari
  • Cali
  • Camperdown
  • Changsha
  • Chelyabinsk
  • Ciudad Autonoma Buenos Aires
  • Cluj-Napoca
  • Cremona
  • Denizli
  • Dubai
  • East Melbourne
  • Edirne
  • Genova
  • Gent
  • Guangzhou
  • Haifa
  • Hangzhou City
  • Hanoi
  • Hasselt
  • Iasi
  • Istanbul
  • Izmir
  • Jinan
  • Kaunas
  • klagenfurt-am-worthersee
  • Kortrijk
  • Krasnoyarsk
  • La Habana
  • Lima
  • Liverpool
  • Liège
  • Malatya
  • Medellín
  • Meldola
  • Montevideo
  • Nanjing
  • Nanning
  • Nis
  • Novara
  • Olomouc
  • Osijek
  • Padova
  • Palermo
  • Panagyurishte
  • Perugia
  • pesochny
  • Petach Tikva
  • Plovdiv
  • Porto
  • Praha 4 - Krc
  • Ramat Gan
  • Reggio Calabria
  • Roma
  • Ronse
  • Santiago
  • Sint-Niklaas
  • Sofia
  • Sremska Kamenica
  • St Leonards
  • Taiyuan
  • Taizhou
  • Tampere
  • Taranto
  • Tel Aviv
  • Tianjin
  • Timisoara
  • Torrette
  • Turku
  • UFA
  • Vila Nova de Gaia
  • Vilnius
  • Wien
  • Wuhan
  • Xuzhou
  • Zagreb
Trial Identifier:

NCT04764188 MO42122

      Show study locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical study see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Study Summary

      This study aims to characterize the clinical management and outcomes of participants diagnosed with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) who are being treated with alectinib in real-world clinical practice.

      Hoffmann-La Roche Sponsor
      N/A Phase
      NCT04764188, MO42122 Trial Identifier
      Alectinib Treatments
      NSCLC Condition
      Official Title

      A Multicenter Non-Interventional Cohort Study to Evaluate the Real-World Clinical Management and Outcomes of Patients Diagnosed With ALK-Positive Advanced NSCLC Treated With Alectinib (ReAlec)

      For the latest version of this information please go to www.forpatients.roche.com

       

      Related Studies

      Use our search to find other trials on Genentech Clinical Trials in related disease areas.

      Non-Small Cell Lung Cancer (NSCLC) Non Small Cell Lung Carcinoma

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now